<DOC>
	<DOCNO>NCT02902809</DOCNO>
	<brief_summary>A 52-Week , Open-Label , Multicentre Study Evaluate Safety Tralokinumab Japanese Adults Adolescents Asthma Inadequately Controlled Inhaled Corticosteroid plus Long-Acting β2-Agonist</brief_summary>
	<brief_title>A Study Evaluate Safety Tralokinumab Adults Adolescents With Uncontrolled Asthma</brief_title>
	<detailed_description>This 52-week , open-label , multi-centre study design evaluate safety tralokinumab fix 300 mg dose every 2 week , administer subcutaneously adults adolescent indequately control asthma medium high dose inhale corticosteroid plus long acting β-2 antagonist . Approximately 26 Japanese subject recruit receive 22 complete .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age 12 75 yr 2 . Documented physiciandiagnosed asthma 3 . Documented treatment inhale corticosteroid ( ICS ) total daily dose correspond ≥500 µg fluticasone propionate dry powder formulation equivalent longacting beta2 agonist ( LABA ) 4 . Prebronchodilator ( BD ) force expiratory volume one second ( FEV1 ) value ≥40 % Predicted Normal Value ( PNV ) 5 . Asthma Control Questionnaire6 ( ACQ6 ) score ≥1.5 1 . Pulmonary disease asthma 2 . History anaphylaxis follow biologic therapy 3 . Hepatitis B , C HIV 4 . Pregnant breastfeed 5 . History cancer 6 . Current tobacco smoke history tobacco smoke ≥10 packyears 7 . Previous receipt tralokinumab</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>open-label study</keyword>
	<keyword>tralokinumab</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>inadequately control asthma</keyword>
	<keyword>asthma</keyword>
	<keyword>medium high-dose inhale corticosteroid</keyword>
	<keyword>long-acting β2-agonist</keyword>
</DOC>